Amikacin dose selection has been created for personal use only. The use of any result generated by this application is in any case the sole risk and responsibility of the user. Therapeutic decision should not solely rely on this applicatoin as the information provided by this tool does not replace clinical judgement. Amikacin dose selection has been validated and realeased in January 2019, there is no guarantee for the accuracy of the provided results. When using Amikacin dose selection you automatically agree with this disclaimer and the legal notices.
The author reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. All offers are not-binding and without obligation. Parts of the pages or the complete publication including all offers and information might be extended, changed or partly or completely deleted by the author without separate announcement.
The author intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object. The copyright for any material created by the author is reserved. Any duplication or use of objects such as images, diagrams, sounds or texts in other electronic or printed publications is not permitted without the author's agreement.
A one-compartment model with linear elimination best describe amikacin time-concentration data. Serum albumin and total bodyweight were included in the amikacin clearance. Concomitant administration of vancomycin and CKD-EPI were included in amikacin clearance. Additional details of the PopPK model development and evaluation are available in the following publications: Perez-Blanco JS, Saez Fernandez EM, Lanao J, Calvo MV, Martin-Suarez A. Amikacin initial dosage in patients with hypoalbuminemia: an interactive tool based on a population pharmacokinetic approach. 2020. Journal of Antimicrobial Chemotherapy, DOI: 10.1093/jac/dkaa158
CL(L/h) = 0.525 + 4.78 x (CKD-EPI/98) x (0.77 x VANCOMYCIN)
V(L) = 26.3 x (ALBUMIN/2.9)-0.51 x [1 + 0.006 x (WGT - 70)]
Where CKD-EPI is the renal function calculated with CKD-EPI equation and expressed in mL/min (deindexed); VANCOMYCIN is 0 or 1 in abcense or co-medication with vancomycin, respectively; ALBUMIN is expresed in g/dL; WGT is total bodyweight in kg.
Important considerations which must be taking into account when applying AMKdose:
Salamanca, 23th July 2020
We are a group of pharmacometrics who work closely with the clinical teams to improve the current treatments.
You can find us at the Pharmaceutical Science Department of the University of Salamanca (Spain).
Jonás Samuel Pérez-Blanco
Don´t hesitate to send us an email to firstname.lastname@example.org.